Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade

Lotte Westerink (), Sharon Wolters, Guiling Zhou, Arjan Postma, Cornelis Boersma, Job Frank Martien Boven and Maarten Jacobus Postma
Additional contact information
Lotte Westerink: University of Groningen, University Medical Center Groningen
Sharon Wolters: University of Groningen, University Medical Center Groningen
Guiling Zhou: University of Groningen
Arjan Postma: Asc Academics B.V
Cornelis Boersma: University of Groningen, University Medical Center Groningen
Job Frank Martien Boven: University of Groningen, University Medical Center, Groningen Research Institute for Asthma and COPD (GRIAC)
Maarten Jacobus Postma: University of Groningen, University Medical Center Groningen

The European Journal of Health Economics, 2025, vol. 26, issue 3, No 8, 455-471

Abstract: Abstract Objectives The aim of this study is to analyse the trends in technology appraisals for non-small cell lung cancer (NSCLC) treatments performed by the National Institute for Health and Care Excellence (NICE) over the last ten years. Methods A systematic search was conducted for single technology appraisals of NSCLC drugs in the online NICE database from 2012 to 2022. Search terms used were ‘non small cell lung cancer’, and ‘NSCLC’. Appraisals that were under development or terminated as well as multiple technology appraisals were considered out of scope. Results In the 30 included appraisals for targeted therapies and immunotherapies within NSCLC, a total of 53 different comparators were included by NICE for 41 assorted indications or subgroups. Partitioned survival models were most frequently used, often including three health states and time horizons of up to 30 years. Throughout the decade the use of indirect comparisons was high and became more established and complex over time. Of all appraisals, 90% positively recommended the treatment for use in the UK. Conclusion Technology appraisals became more complex over time due to the emergence of targeted therapies and immunotherapies, leading to multiple different indications, subpopulations and comparators that needed to be included in appraisals. Partitioned Survival Analysis (PartSA) models became the cornerstone within NSCLC, with time horizons up to 30 years and over time methods for indirect treatment comparisons became more established. The majority of the appraisals resulted in a positive recommendation for reimbursement.

Keywords: NSCLC; HTA; Cost-effectiveness; Review; Technology appraisals; NICE; UK (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-024-01711-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:26:y:2025:i:3:d:10.1007_s10198-024-01711-0

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-024-01711-0

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().